U.S. markets rose on the last day of the first quarter. All but the energy sector posted gains in the S&P 500 Index, with the biotechnology sector leading the way. The S&P 500 Index gained 0.79 percent, up 1.3 percent in the first quarter of 2014, while the Nasdaq gained 1.04 percent, up 0.54 percent in the first quarter. "We're starting the second quarter pretty much where we started the first quarter—not much changed and still concerns about whether we'll see the arrival of better growth," said Kate Warne, investment strategist at Edward Jones. Here is how some Biotech companies reacted Monday:
BioTime, Inc. (NYSEMKT: BTX) shares traded in the range of $3.01 to $3.29 Monday before settling to close at $3.29, an increase of 5.79 percent. The stock appears to be facing some resistance at the $3.32 and $3.50 levels with some support at $3.26. Shares of BioTime are down approximately 8.0 percent year-to-date.
More information on BioTime and access to the free equity report can be found at:
www.WallStreetFundamentals.com/BTX
Corcept Therapeutics Inc. (NASDAQ: CORT) shares traded in the range of $4.14 to $4.47 Monday before settling to close at $4.36, an increase of 7.13 percent. The stock appears to be facing some resistance at $4.90 with some support at the $4.01 and $3.81 levels. Shares of Corcept Therapeutics are up approximately 35.0 percent year-to-date.
More information on Corcept Therapeutics and access to the free equity report can be found at:
www.WallStreetFundamentals.com/CORT
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) shares traded in the range of $1.68 to $1.74 Monday before settling to close at $1.73, an increase of 4.85 percent. The stock appears to be facing some resistance at the $1.83 and $1.90 levels with some support at $1.72. Shares of Lexicon Pharmaceuticals are down approximately 4.0 percent year-to-date.
More information on Lexicon Pharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/LXRX
Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) shares traded in the range of $6.07 to $6.71 Monday before settling to close at $6.61, an increase of 5.93 percent. The stock appears to be facing some resistance at the $6.70 and $7.13 levels with some support at $6.10 and $5.72. Shares of Sunesis Pharmaceuticals are up approximately 40.0 percent year-to-date.
More information on Sunesis Pharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/SNSS
Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.
Activate your always free membership by signing up at www.WallStreetFundamentals.com today.
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Wall Street Fundamentals
Website: www.WallStreetFundamentals.com
Email: [email protected]